Loading...
•
Mar 31, 2022
ANI Pharmaceuticals Q1 2022 Earnings Report
ANI Pharmaceuticals reported first quarter results with a net loss and a diluted GAAP loss per share.
Key Takeaways
ANI Pharmaceuticals reported first quarter net revenues of $64.5 million and a net loss of $(20.1) million, with a diluted GAAP loss per share of $(1.27). The company launched Cortrophin Gel and is increasing its full-year net revenue guidance.
Launched Cortrophin Gel and provided 2022 Net Revenue guidance of $35 million to $40 million.
Increased full-year net revenue guidance to $295 million to $315 million.
Launched several new products, including Misoprostol Tablets, Rifabutin Capsules, and Bisoprolol Tablets.
Filed six new ANDA applications.
Revenue by Segment
Forward Guidance
ANI is initiating guidance on Cortrophin Gel specific Net Revenue, total Company Net Revenue, total Company adjusted non-GAAP EBITDA, and total Company adjusted non-GAAP Diluted Earnings per Share, and is reiterating its previous guidance on total Company research and development expense and Cortrophin Gel Selling, General and Administrative expense.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...